Lumbar myelography

Area of Science:

• Radiology
• Neurology
• Pharmacology

Background:

• Lumbar myelography is a key diagnostic imaging technique.
• Metrizamide (Amipaque) is a contrast agent used in myelography.
• Assessing the safety and efficacy of contrast agents is crucial.

Purpose of the Study:

• To evaluate the incidence of side effects associated with metrizamide lumbar myelography.
• To determine the diagnostic reliability of metrizamide in lumbar myelography.
• To analyze adverse events in a large patient cohort.

Main Methods:

• Review of 48,000 lumbar myelographies performed with metrizamide up to November 1976.
• Detailed analysis of adverse effects and diagnostic accuracy in 2,457 examinations from Ullevål Sykehus.
• Recording and categorization of side effects, including epileptic seizures.

Main Results:

• A low rate of minor side effects was observed.
• High diagnostic accuracy was achieved with metrizamide myelography.
• Three epileptic seizures were recorded; two occurred in patients with known epilepsy.

Conclusions:

• Metrizamide (Amipaque) is associated with a low incidence of adverse effects in lumbar myelography.
• The diagnostic accuracy of metrizamide myelography is high.
• The risk of serious adverse events like seizures appears low, particularly in non-epileptic patients.